Cost-Effectiveness of Universal and Platelet Reactivity Assay-Driven Antiplatelet Therapy in Acute Coronary Syndrome
Authors:
- Craig I. ColemanCCCraig I. Coleman
- Brendan L. LimoneBLBrendan L. Limone
- 1 August 2013
- journal article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 112 (3) , 355-362
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary StentingNew England Journal of Medicine, 2012
- Pharmacodynamic Effect of Switching Therapy in Patients With High On-Treatment Platelet Reactivity and Genotype Variation With High Clopidogrel Dose Versus PrasugrelCirculation: Cardiovascular Interventions, 2012
- Primary and Secondary Prevention of Cardiovascular DiseaseChest, 2012
- Cost Estimation of Cardiovascular Disease Events in the USPharmacoEconomics, 2011
- Ticagrelor versus Genotype-Driven Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndrome: A Cost-Effectiveness AnalysisValue in Health, 2011
- Prospective Evaluation of On-Clopidogrel Platelet Reactivity Over Time in Patients Treated With Percutaneous Coronary InterventionJACC, 2011
- Cardiovascular Death and Nonfatal Myocardial Infarction in Acute Coronary Syndrome Patients Receiving Coronary Stenting Are Predicted by Residual Platelet Reactivity to ADP Detected by a Point-of-Care AssayCirculation, 2009
- Cost-Effectiveness of Providing Full Drug Coverage to Increase Medication Adherence in Post–Myocardial Infarction Medicare BeneficiariesCirculation, 2008
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007
- Cost-Effectiveness of Echocardiography to Identify Intracardiac Thrombus among Patients with First Stroke or Transient Ischemic AttackMedical Decision Making, 2007